PCCI affects a subset of cancer survivors, though the overall epidemiology and prevalence is not well known and may depend on many factors. It generally affects about 10–40% of breast cancer patients, with higher rates among pre-menopausal women and patients who receive high-dose<unk> .
Post-chemotherapy cognitive impairment
Paraneoplastic syndrome
Postmenopausal confusion
Postoperative cognitive dysfunction
AIDS fatigue
Sleeping disorders following traumatic brain injury
Autoimmune disease in women
Chemotherapy-induced peripheral neuropathy